Affini-T Therapeutics, Inc.

Moderna has walked away from an alliance with Metagenomi that could have been worth up to $4bn, returning exclusive rights to its gene-editing technologies and preclinical pipeline. Moderna’s withd

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

ElevateBio, LLC launched in 2019 as a cell and gene therapy R&D and manufacturing hub for its subsidiary companies and partners, and with demand for its know-how growing, the firm has raised $410m in